Liquidia Corporation (LQDA)
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Liquidia Corporation - LQDA
NEW YORK, NY / ACCESSWIRE / September 5, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Liquidia Corporation ("Liquidia" or the "Company") (NASDAQ:LQDA). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
An Investigation Has Commenced on Behalf of Liquidia Corporation Shareholders. Contact Levi & Korsinsky to Discuss your LQDA Losses.
NEW YORK, NY / ACCESSWIRE / September 5, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Liquidia Corporation ("Liquidia Corporation") (NASDAQ:LQDA) concerning possible violations of federal securities laws. On August 19, 2024, Liquidia shares have dropped 35% following an announcement that the FDA has postponed final approval of Liquidia's Yutrepia drug treating adults with pulmonary diseases.
Investors Impacted By Liquidia Corporation's Possible Securities Fraud Should Join The Schall Law Firm In An Inquiry
LOS ANGELES, CA / ACCESSWIRE / September 5, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Liquidia Corporation ("Liquidia" or "the Company") (NASDAQ:LQDA) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
Lost Money on Liquidia Corporation (LQDA)? Contact Levi & Korsinsky Regarding an Ongoing Investigation
NEW YORK, NY / ACCESSWIRE / September 5, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Liquidia Corporation ("Liquidia Corporation") (NASDAQ:LQDA) concerning possible violations of federal securities laws. On August 19, 2024, Liquidia shares have dropped 35% following an announcement that the FDA has postponed final approval of Liquidia's Yutrepia drug treating adults with pulmonary diseases.
Bronstein, Gewirtz & Grossman, LLC Encourages Liquidia Technologies, Inc.(LQDA) Stockholders to Inquire about Securities Investigation
NEW YORK, NY / ACCESSWIRE / September 5, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Liquidia Technologies, Inc. ("Liquidia" or "the Company") (NASDAQ:LQDA). Investors who purchased Liquidia securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/LQDA.
Levi & Korsinsky Reminds Shareholders of an Investigation into Liquidia Corporation (LQDA) Regarding Potential Securities Fraud Allegations
NEW YORK, NY / ACCESSWIRE / September 4, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Liquidia Corporation ("Liquidia Corporation") (NASDAQ:LQDA) concerning possible violations of federal securities laws. On August 19, 2024, Liquidia shares have dropped 35% following an announcement that the FDA has postponed final approval of Liquidia's Yutrepia drug treating adults with pulmonary diseases.
Liquidia Corporation Is Being Looked Into For Possibly Violating Securities Regulations And The Schall Law Firm Seeks Shareholders With Losses
LOS ANGELES, CA / ACCESSWIRE / September 4, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Liquidia Corporation ("Liquidia" or "the Company") (NASDAQ:LQDA) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Liquidia Technologies, Inc.(LQDA) and Encourages Investors to Learn More About the Investigation
NEW YORK, NY / ACCESSWIRE / September 4, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Liquidia Technologies, Inc. ("Liquidia" or "the Company") (NASDAQ:LQDA). Investors who purchased Liquidia securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/LQDA.
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Liquidia Technologies, Inc.(LQDA) And Encourages Investors to Reach Out
NEW YORK, NY / ACCESSWIRE / September 3, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Liquidia Technologies, Inc. ("Liquidia" or "the Company") (NASDAQ:LQDA). Investors who purchased Liquidia securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/LQDA.
LQDA ALERT: Levi & Korsinsky Reminds Investors of an Investigation Involving Possible Securities Fraud Violations by Liquidia Corporation
NEW YORK, NY / ACCESSWIRE / September 2, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Liquidia Corporation ("Liquidia Corporation") (NASDAQ:LQDA) concerning possible violations of federal securities laws. On August 19, 2024, Liquidia shares have dropped 35% following an announcement that the FDA has postponed final approval of Liquidia's Yutrepia drug treating adults with pulmonary diseases.
Liquidia Corporation Investigation Ongoing: Contact Levi & Korsinsky About Potential Securities Fraud Allegations - LQDA
NEW YORK, NY / ACCESSWIRE / September 2, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Liquidia Corporation ("Liquidia Corporation") (NASDAQ:LQDA) concerning possible violations of federal securities laws. On August 19, 2024, Liquidia shares have dropped 35% following an announcement that the FDA has postponed final approval of Liquidia's Yutrepia drug treating adults with pulmonary diseases.
Liquidia Corporation Is Being Looked Into For Potential Infractions Of Securities Laws And The Schall Law Firm Invites Shareholder Participation
LOS ANGELES, CA / ACCESSWIRE / September 2, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Liquidia Corporation ("Liquidia" or "the Company") (NASDAQ:LQDA) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
